Bone cancer primary bone cancers and bone metastases
| Otros Autores: | |
|---|---|
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
San Diego, California ; Waltham, Massachusetts :
Elsevier/Academic Press
2015.
|
| Edición: | 2nd ed |
| Colección: | Science Direct e-books.
|
| Acceso en línea: | Conectar con la versión electrónica |
| Ver en Universidad de Navarra: | https://innopac.unav.es/record=b4206742x*spi |
Tabla de Contenidos:
- Epidemiology of primary bone tumors and economical aspects of bone metastases
- Tumor: bone interactions: there is no place like bone
- Stem cell niches in the bone: bone marrow organ and their significance for hematopoietic and non-hematopoietic cancer
- Deregulation of osteoblast differentiation in primary bone cancers
- Contribution of osteoclasts to the bone: tumor niche
- Involvement of osteocytes in cancer bone niche
- Role of mesenchymal stem cells in bone cancer; initiation, propagation and metastasis
- Gap junction in bone remodeling and in primary bone tumors: osteosarcoma and Ewing sarcoma
- Macrophages and pathophysiology of bone cancers
- Cytokines and bone cancers
- Technical aspects: how do we best prepare bone samples for proper histological analysis?
- Bone remodeling markers and bone cancer
- Cancer stem cells in representative bone tumors: osteosarcoma, Ewing sarcoma and metastases from breast and prostate carcinomas
- Homeobox genes from the Dlx family and bone cancers
- MicroRNA implication in therapeutic resistance and metastatic dissemination of bone-associated tumors
- Hypoxia and angiogenesis: from primary tumor to bone metastasis
- Modeling osteosarcoma: in vitro and in vivo approaches
- Stemness markers of osteosarcoma
- Molecular pathology of osteosarcoma
- Gene and proteomic profiling of osteosarcoma
- Ewing sarcoma family of tumors
- Biology of Ewing sarcoma
- Osteoclast-rich lesions of bone: a clinical and molecular overview
- Markers for bone sarcomas
- Margins and bone tumors: what are we talking about?
- Cytogenetics of bone tumors
- Genetic aspects of bone tumors
- Cytogenetic and molecular genetic alterations in bone tumors
- Genetics of giant cell tumors of bone
- Mammalian models of bone sarcomas
- Zebrafish models for studying bone cancers: mutants, transgenic fish and embryos
- Imaging of bone sarcomas
- New therapeutic targets in Ewing sarcoma: from pre-clinical proof-of-concept to clinical trials
- Therapeutic approaches for bone sarcomas
- Chondrosarcoma of bone: diagnosis and therapy
- Apoptosis and drug resistance in malignant bone tumors
- Giant cell tumors of bone
- EMT process in bone metastasis
- Histopathology of skeletal metastases
- Disseminated tumor cells in bone marrow of cancer patients.
- MicroRNA-mediated regulation of bone metastasis formation: from primary tumors to skeleton
- Myeloma and osteoclast relationship
- In vivo models used in studies of bone metastases
- Interventional radiologic techniques in management of bone tumors
- Diagnosis of bone metastases in urological malignancies : an update
- Pre-clinical molecular imaging of "the seed and the soil" in bone metastasis
- Mechanisms and management of bone cancer pain
- Bone cancer: current opinion in palliative care
- Involvement of sympathetic nerves in bone metastasis
- Pain control with palliative radiotherapy in patients with bone metastases
- Cellular and molecular actions of bisphosphonates
- The use of nitrogen-bisphosphonates to capture the potent anti-tumor arsenal of human peripheral blood [gamma delta] T cells for the treatment of bone cancer metastasis
- Systemic treatment of bone metastases in castration-resistant prostate cancer (CRPC): pre-clinical to clinical point of view
- A multi-targeted approach to treating bone metastases
- Bone metastases in prostate cancer: pathophysiology, clinical complications, actual treatment, and future directions
- Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases
- Bone metastases : current status of bone-targeted treatments
- Bone metastases, clinical trials II: zoledronic acid and denosumab in the prevention of bone metastases.
